Effect of Radiotherapy Combined With Pembrolizumab on Local Tumor Control in Mucosal Melanoma Patients

Hyun Ju Kim¹, Jee Suk Chang²*, Mi Ryung Roh³, Byung Ho Oh⁴, Kee-Yang Chung⁴, Sang Joon Shin⁵* and Woong Sub Koom²

¹Department of Radiation Oncology, Gachon University Gil Hospital, Incheon, South Korea, ²Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea, ³Department of Dermatology, Cutaneous Biology Research Institute, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea, ⁴Department of Dermatology, Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, South Korea, ⁵Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea

Objective: Mucosal melanoma is an aggressive malignancy with a poor response to conventional therapies. The efficacy of radiotherapy (RT), especially combined with immune checkpoint inhibitors (ICIs), for this rare melanoma subtype remains unknown. We investigated the reciprocal effect of RT and ICI on mucosal melanoma patients.

Materials and Methods: We identified 23 patients with 31 tumors who were treated with RT between July 2008 and February 2017. All patients received RT for primary or metastatic gross tumor mass with a median dose of 4 Gy per fraction (range 1.8–12 Gy). Eleven patients (14 lesions) were treated with RT alone, whereas 12 (17 lesions) were administered pembrolizumab combined with RT (ICI+RT group). The local control (LC) and adverse event (AE) rates were compared between the groups. Eight patients with metastatic mucosal melanoma treated with ICI alone during the same study period were included as a comparison group.

Results: The median follow-up period was 17.4 (range 3.7–95.2) months. The target lesion control rate at 1-year was significantly higher in the ICI+RT group than in the RT-alone group or ICI-alone group (94.1% vs. 57.1% vs. 25%; P < 0.05). No abscopal effect was observed in our cohort. Treatment-related AEs were not significantly increased in the combined treatment group compared with the RT-alone group (P > 0.05). No grade ≥3 AEs occurred in the ICI+RT group.

Conclusions: Besides RT acting as an immune adjuvant, ICI might have a radiosensitizing effect and may increase LC without severe toxicity. We have initiated a phase II study to determine the effects of RT in patients with melanoma undergoing anti-PD1 (NCT04017897).

Keywords: melanoma, immunotherapy, radiotherapy, local control, adverse events
INTRODUCTION

Mucosal melanoma is a rare malignancy, accounting for only 1–4% of all melanomas (1, 2). It originates from melanocytes in the mucosal surfaces of the nasal sinuses, oral cavity, vagina, anus, and other areas. Mucosal melanoma has a behavioral pattern that is distinct from that of cutaneous melanomas. Besides its distinct presentation, mucosal melanoma has an aggressive prognosis, given its high rates of local failure and distant metastasis (3, 4). The overall 5-year survival rate is low, ranging from 20 to 30% (5, 6). As for cutaneous melanoma, wide surgical resection is the primary treatment of choice for localized mucosal melanoma. Historically, melanoma was regarded as being resistant to conventional RT (7), although this aspect remains controversial. Concerning the treatment of mucosal melanoma, a few studies have reported improved local control (LC) with postoperative RT use (8–10). However, the role of RT remained limited before the introduction of immune checkpoint inhibitors (ICIs). Systemic chemotherapy for improving treatment outcomes in mucosal melanoma remains unknown.

In the immunotherapy era, conventional assumptions regarding RT for melanoma have been challenged. Recently, ICIs have become the major treatment modality for some cancers, most distinguishably, malignant melanoma. Ipilimumab (an anti-cytotoxic T-lymphocyte antigen-4 antibody), nivolumab, and pembrolizumab (an anti-programmed-death 1 monoclonal antibody) were approved by the United States Food and Drug Administration for advanced melanoma patients (11–13). Despite the advent of ICIs, numerous patients do not respond to ICI and develop adverse events (AEs). Preclinical and clinical studies suggest that RT induces a systemic immune response to tumors outside of the radiation target (14–16). However, data analyzing the reciprocal radiosensitizing effects of ICI on LC are scarce. Furthermore, the efficacy of ICI with RT for mucosal melanoma, a rarer and more radioresistant entity of melanoma, remains unknown. We aimed to investigate the efficacy and safety of RT combined with pembrolizumab in mucosal melanoma patients.

METHODS

Study Population

Patients treated for mucosal melanoma between July 2008 and December 2018 were identified from our institutional database. Mucosal melanomas were tumors arising from mucous membranes, such as those in the head and neck, anorectum, female genital tract, and urinary tract. Ocular melanomas, including tumors involving the conjunctiva and uvea, were excluded. Histological confirmation of the lesion was essential for all cases. We included patients receiving RT for gross tumor lesions, either at the primary site or a metastatic lesion. Among 33 patients, those not completing RT (n = 5) and lost to follow-up (n = 5) were excluded. Ultimately, 23 patients treated for 31 lesions were included. During the study period, at our institution, we then included 8 patients treated with ICI alone for mucosal melanoma to investigate the possibility of an effect of ICI on local control.

Clinical information regarding demographic data, subsite of origin, staging, surgical resection, adjuvant treatment, and outcome was retrieved. All patients were staged according to the 7th American Joint Committee on Cancer staging system for each anatomical site, given that there is no staging system that can integrate staging of mucosal melanoma. Metastasis staging was based on cutaneous melanoma criteria. This retrospective study was reviewed and approved by the institutional review board of the Yonsei University Health System (IRB 4-2017-1187). The patient records/data were anonymized and de-identified before analysis, and the requirement for informed consent was waived.

Treatment

At our institution, the basic treatment principle for patients without distant metastasis at presentation was primary surgical resection if the lesion was resectable, followed by adjuvant interferon therapy, chemotherapy, or adjuvant RT. Adjuvant treatment was decided upon according to the disease extent and clinician’s judgment. For patients diagnosed with stage IV disease, chemotherapy with dacarbazine was primarily considered before the ICI era. ICI became the first-line treatment after its approval for metastatic melanoma patients. Pembrolizumab (Keytruda®, Merck), an anti-programmed cell death-1 (PD-1) antibody, was administered intravenously at 2 mg/kg doses every 2 or 3 weeks. Local RT was considered if a solitary gross mass or symptomatic lesion existed. The radiation dose was determined depending on the anatomic site and indication. The median dose of radiation was 40 (range 20–69) Gy, with a median fractional dose of 4 (range 1.8–12) Gy. Pembrolizumab and RT administered to any lesion was considered concurrent treatment if RT was performed within 4 weeks after initiating or ending ICI; all other approaches were defined as non-concurrent treatment.

Follow-Up

Patients were medically evaluated before administering pembrolizumab. During RT, all patients were examined once a week. Acute toxicities were recorded and graded according to the Common Terminology Criteria for Adverse Events (v4.01). After completing the scheduled treatment, regular follow-up was conducted every 1–3 months with imaging studies. All treated lesions were measured according to the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by computed tomography or magnetic resonance imaging, as available; complete response (CR); partial response (PR): ≥30% decrease in the sum of the largest diameters of the target lesions, relative to baseline; progressive disease (PD): ≥20% increase in the sum of the largest diameters of the target lesions, relative to the sum of the smallest diameter recorded, or the appearance of one or more new lesions; or stable disease (SD): neither PR nor PD (17). For patients treated with ICI alone, the response was evaluated according to the immune RECIST criteria (18). The objective response rate (ORR) was defined as the proportion of patients achieving CR or PR.
**Statistical Analysis**

To compare patient demographics, *P* values were determined using the *χ²* test or Fisher’s exact test for categorical variables and one-way analysis of variance for continuous variables. The primary endpoints were LC rates and AEs in mucosal melanoma patients treated with RT ± pembrolizumab or ICI alone. The secondary endpoints were progression-free survival (PFS) and overall survival (OS). Each endpoint was compared between the groups (ICI+RT vs. RT alone vs. ICI alone). PFS was determined from the date of initiating RT to the corresponding event, whereas OS was calculated from the date of diagnosis to the date of death or loss to follow-up. The Kaplan–Meier method with the log-rank test was used to analyze survival outcomes. All statistical tests were two-sided, with significance defined as *P* < 0.05. All data were analyzed using IBM SPSS software version 23.0 (SPSS Inc., Chicago, IL, USA).

**RESULTS**

Overall, 31 patients were analyzed in this study. Four patients received RT for two lesions each, and two patients, for three lesions sequentially. Eleven patients with 14 lesions and 12 patients with 17 lesions were included in the RT alone and ICI+RT groups, respectively. Eight patients were included in ICI alone group. Details on patient and treatment characteristics are summarized in Tables 1, 2.

**Patients Treated With Radiotherapy Alone**

Eleven patients were treated with RT alone for 14 lesions, including 5 primary sites and 9 metastatic lesions. The median age was 48 (range 39–73) years. Subtype of mucosal melanoma was head and neck in 8 (72.7%) and anorectum in 3 patients (27.3%). Six (54.5%) patients previously received resection for a primary lesion. Six (54.5%) patients received one or more prior lines of systemic therapy for advanced disease. The radiation dose was a median of 3 Gy (range 2–12) per fraction and a median of 45 Gy (range 20–69) in total. BRAF mutation status was reported in 4 (36.4%) patients, and one had a BRAF mutation.

**Patients Treated With Radiotherapy Combined With Immune-Checkpoint Inhibitor**

Twelve patients were administered pembrolizumab combined with RT, concurrently in 11 patients and sequentially in 1 patient for whom pembrolizumab was administered 7 months before initiating RT. The median interval between the first administration of pembrolizumab and initiating RT was 9 (range 0–214) days. The number of treated lesions were 17, including 7 primary and 10 metastatic lesions. The median age was 58 (range 32–81) years. Subtype was head and neck in 5 (41.7%), anorectum in 4 (33.3%), and genitourinary tract in 3 (25%) patients, respectively. Radiation dose was median 5 Gy (range 1.8–8) per fraction and median 36 Gy (range 20–60) in total. A BRAF mutation was reported in half of the patients in whom no BRAF mutation was detected.

**Patients Treated With Immune-Checkpoint Inhibitor Alone**

Eight patients were diagnosed with stage IV disease and received ICI as the first treatment, except two patients who previously performed first-line chemotherapy. Six patients administered pembrolizumab and two patients received ipilimumab. The median age was 59 (range 48–73) years and all patients had head and neck subtype except for 1 patient who had anorectal melanoma. No BRAF mutation was detected among 5 patients whose mutation status was known.

**Infield LC and Response Rate**

The median follow-up period was 17.4 (range 3.7–95.2) months. The median follow-up periods were 14 (range 3.7–95.2), 21.9 (range 9.2–56.9), and 9 (range 4–35) months for the ICI+RT,
| No | Primary | BRAF | c-kit | LDH (IU/L) | Initial M stage | Previous treatment | Site irradiated | ICI | RT dose | RT technique | Best response | Outfield response |
|----|---------|------|-------|-----------|-----------------|-------------------|------------------|-----|---------|-------------|---------------|------------------|
| 1  | Maxilla | NR   | NR    | 194       | M1              | DTIC/IFN          | Primary site     | No  | 60 Gy/30fx | IMRT         | PR            | PD               |
| 2  | Nasal cavity | NR | NR    | 164       | M0              | DTIC/IFN          | Primary site     | No  | 69 Gy/23fx | IMRT         | PR            | PD               |
| 3  | Nasal cavity | NR | NR    | 231       | M0              | Resection + PORT  | Sacrum           | No  | 20 Gy/5fx  | IMRT         | SD            | PD               |
| 4  | Nasopharynx | WT  | WT    | 119       | M0              | No                | Primary site     | No  | 64 Gy/32fx | IMRT         | PR            | PD               |
| 5  | Rectum | WT   | NR    | 200       | M1              | No                | Primary site     | No  | 45 Gy/15fx | 3D-CRT       | PR            | PD               |
| 6  | Rectum | NR   | NR    | 195       | M1              | No                | Brain            | No  | 45 Gy/15fx | 3D-CRT       | SD            | PD               |
| 7  | Buccal mucosa | NR | NR    | 2,013     | M0              | Multiple resection, DTIC | Rt. cheek mass | No  | 39 Gy/13fx | IMRT         | PD            | PD               |
| 8  | Anus   | WT   | WT    | 187       | M0              | Resection + PORT  | Rt. humerus, Lt. scapula | Pembrolizumab | 37.5 Gy/5fx, 40 Gy/10fx | 3D-CRT       | SD, SD        | PD               |
| 9  | Nasal cavity | Codon 601 | WT | WT    | 183       | M0              | Resection + PORT, DTIC, Taxol/carbo | Liver, mediastinal LN, abdominal nodule | Pembrolizumab | 45 Gy/15fx, 40 Gy/10fx, 40 Gy/10fx | IMRT         | SD, PR, PD     | PD               |
| 10 | Nasal cavity | WT | NR    | 204       | M0              | Multiple resection, DTIC | Neck node | No  | 66 Gy/30fx | IMRT         | PR            | PD               |
| 11 | Anorectal | NR  | NR    | 143       | M0              | Resection         | Paravertebral muscle, Lt. paravertebral muscle, Rt. node | Pembrolizumab | 50 Gy/25fx | IMRT         | PR            | PD               |
| 12 | Maxilla | NR   | NR    | 201       | M0              | Resection         | Recurrent neck node | Pembrolizumab | 50 Gy/20fx | IMRT         | PR            | PD               |
| 13 | Buccal mucosa | NR | NR    | 258       | M0              | DTIC, Taxol/carbo | MMS, wide excision | Primary site | Pembrolizumab | 45 Gy/25fx | 3D-CRT       | PR            | PD               |
| 14 | Vulva   | NR   | NR    | 2,799     | M0              | No                | Pelvic nodule | Pembrolizumab | 20 Gy/10fx | 3D-CRT       | SD            | SD               |
| 15 | Anorectal | WT  | NR    | 215       | M0              | No                | Abdominal nodule | Pembrolizumab | 40 Gy/10fx | 3D-CRT       | SD            | PD               |
| 16 | Vulva   | WT   | WT    | 212       | M0              | Resection, IFN, DTIC, Taxol/carbo | Spleen | Pembrolizumab | 40 Gy/10fx | 3D-CRT       | SD            | PD               |
| 17 | Nasal cavity | NR | NR    | 145       | M1              | No                | Primary site     | Pembrolizumab | 60 Gy/25fx | IMRT         | PR            | PD               |
| 18 | Nasal cavity | WT | WT    | 191       | M0              | No                | Primary site     | Pembrolizumab | 59.2 Gy/27fx | IMRT         | PR            | PD               |
| 19 | Vagina  | WT   | WT    | 203       | M0              | No                | Primary site     | Pembrolizumab | 36 Gy/6fx  | IMRT         | CR            | SD               |
| 20 | Rectum  | WT   | WT    | 229       | M1              | No                | Primary site, pancreatic mass, lung | Pembrolizumab | 30 Gy/6fx, 25 Gy/6fx, 30 Gy/6fx | IMRT         | SD, PR, SD     | PD               |
| 21 | Urethra | WT   | WT    | 166       | M0              | No                | Primary site, inguinal LN | Pembrolizumab | 30 Gy/6fx, 30 Gy/6fx, 30 Gy/6fx | 3D-CRT       | PR, PR, PD     | PD               |
| 22 | Nasal cavity | NR | NR    | 249       | M0              | No                | Primary site     | Pembrolizumab | 55 Gy/25fx | IMRT         | PR            | PD               |
| 23 | Vulva   | NR   | NR    | 271       | M0              | No                | Primary site, lung | Pembrolizumab | 30 Gy/6fx, 24 Gy/6fx | IMRT         | SD, SD        | PD               |

LDH, lactate dehydrogenase; ICI, immune checkpoint-inhibitor; RT, radiotherapy; fx, fractions; WT, wild type; NR, not reported.
RT-alone, and ICI-alone groups, respectively. The 1-year LC rate was 94.1, 57.1, and 25% for the ICI+RT, RT-alone, and ICI-alone groups, respectively, and was significantly better in the ICI+RT combination group ($P < 0.005$; Figure 1). Of 31 lesions treated with RT, 1 showed CR and 16 showed PR, for an infield ORR of 54.8%. SD and PD were observed in 13 and 1 lesions, respectively. The infield ORRs were similar for the ICI+RT and RT-alone groups (52.9% vs. 57.1%; $P = 0.815$). However, once obtained, the response was maintained longer in the ICI+RT group than in the RT-alone group, although the follow-up period was relatively short in the ICI+RT group (Figure 2). The target lesion volume of the ICI+RT group showed decreasing tendency, whereas changes in the target lesion volume of the RT-alone group varied. Among 8 patients treated with ICI alone, 6 experienced PD and 2 had CR, with an ORR of 25%. The waterfall plot for all patients is illustrated in Figure 3.

**Treatment-Related Adverse Events**
Radiation-related adverse events were observed in 12 (52.2%) of 23 patients (Table 3). Overall, the most frequently reported AE was Grade 1 or 2 fatigue. Grade 3 AEs were reported by 3 (13.0%) patients, including G3 mucositis in 2 and G3 gastrointestinal disorder in 1 patient. There was no Grade 4 or higher treatment-related AE. All AEs were transient and manageable with conservative management. Regarding AEs based on treatment sites, 8/12 patients were treated for their primary lesions, whereas 4 were treated for the metastatic mass located in the abdominopelvic area. The combination of RT and pembrolizumab did not increase AE incidence. No statistically significant differences existed in the incidence of any AEs between the two groups. Among patients treated with ICI alone, there was no grade 3 or higher AE observed.

**Survival Outcomes**
The 1- and 2-year OS rates were 90.4 and 56.0%, respectively, for all patients. The 2-year OS rates were 85.7, 42.9, and 65.6% for the ICI+RT, RT-alone, and ICI-alone groups, respectively; however, the difference was not statistically significant ($P = 0.095$; Figure 4). The 1-year PFS rates were 0, 7.1, and 25.0% for the ICI+RT, RT-alone, and ICI-alone groups, respectively ($P = 0.727$; Figure 4). Almost all patients experienced outfi eld tumor progression during the follow-up period. No abscopal effect was observed in our cohort. Clinical factors including gender, age, subtype, and lactate dehydrogenase were not significantly associated with OS or PFS. We could not include BRAF and c-kit mutations in the analysis as the mutational status was not reported in more than half of the patients.

**DISCUSSION**
Mucosal melanoma has biological and epidemiological features distinct from those of cutaneous melanoma. In the management of cutaneous melanoma, a remarkable evolution has recently occurred with the introduction of ICI. Response rates have improved (20–45%) in metastatic melanoma patients treated with anti-PD-1 monotherapy (12, 18, 19). However, because of its rarity, only a few studies have investigated the efficacy of ICI in mucosal melanoma (20–22). Shoushtari et al. revealed that the ORR of anti-PD-1 agents nivolumab or pembrolizumab was 23% in mucosal melanoma patients, with a median PFS of 3.9 months, which was comparable to previously published rates in cutaneous melanoma patients (20). D’Angelo et al. isolated a mucosal melanoma subtype from cutaneous melanoma and revealed that metastatic mucosal melanoma patients benefitted from ICI (22). Altogether, the current evidence implies that the response rate for ICI may not be different in mucosal melanoma, although the overall prognosis is poorer for mucosal melanoma patients.

To improve ICI efficacy, it is combined with other treatment modalities, and RT can be one of optimal candidate. Among various cancer histologies, melanomas are intrinsically radioresistant, as shown by cell culture studies (23). Interestingly, recent evidence suggests the possibility that immunity could also affect LC. Lee et al. found that RT induced upregulation of the immune response by increasing T-cell infiltration into the tumor microenvironment (TME), which induced significant tumor regression in wild-type mice, whereas tumors remained radioresistant to RT in nude mice, in which T cells were absent (24). This result suggests that the immune system is crucial for eliciting therapeutic effects of RT. Furthermore, in radioresistant tumors, namely, melanoma, whether the activation of the immune system improves the clinical efficacy of RT in terms of LC needs to be clarified.

For mucosal melanoma, wide surgical excision is the only effective approach to control macroscopic disease spread, and RT may be used selectively to control the microscopic disease. Several series have reported a suboptimal LC rate with RT alone in unresectable mucosal melanoma cases. The Northern Japan Radiation Therapy Oncology Group reported about 31 patients treated with definitive RT using a 50-Gy median dose for unresectable head and neck mucosal melanoma. The CR and PR rates were 29 and 58%, respectively, with a tumor control rate of 61% (25). Another study showed a 3-year actuarial LC rate of 49%
using a radiation dose of 50–55 Gy in 15–16 fractions (26). In a randomized study comparing the effectiveness of two different RT schedules in treating soft-tissue and nodal metastasis, the ORR was 59% and CR rate was 24% (27). In our study, the ORR for RT was 54.8% for all gross lesions, which is similar to previous results. The response rate of RT is high by itself, given that the response rate in the previously reported melanoma trials of PD-1 blockade with nivolumab or pembrolizumab was 23–31% (22, 28, 29). RT may be a good treatment modality for LC when the tumor is unresectable, as is common in clinical practice.

Various preclinical studies have demonstrated that RT interacts with the immune system (14, 30, 31). This interaction can stimulate and suppress the immune system, depending on the radiation volume, dose fraction size, and tumor environment. RT causes the death of tumor cells and improves the ability of the immune system to recognize tumors by releasing tumor-associated antigens and immunostimulatory compounds within the tumor (14, 16). Sub-ablative doses of RT could increase dendritic cell activation and T-cell priming, and low-dose radiation can increase tumor-infiltrating lymphocytes by breaking down the stroma and inducing macrophage differentiation. Thus, the invasion of primed CD8+ T cells and other effector cells into the TME is promoted, providing a localized antitumor immune response. Furthermore, as previously reported in 2012 (32), immune effector cells locally primed by RT recognize and destroy tumors in non-irradiated...
Kim et al. RT Combined With Anti-PD-1 in Mucosal Melanoma

TABLE 3 | Radiation-related adverse events.

| CTCAE category                        | Adverse events | RT alone (N = 11) | ICI+RT (N = 12) | P value |
|--------------------------------------|----------------|------------------|-----------------|---------|
| Gr 1 | Gr 2 | Gr 3 | Gr 4+ | All (%) | Gr 1 | Gr 2 | Gr 3 | Gr 4+ | All (%) | P value |
| General disorders (Fatigue, anorexia)| 6 0 0 0 6 (54.5) | 2 2 0 0 4 (33.3) | 0.305 |
| Gastrointestinal disorders           | 0 1 1 0 2 (18.2) | 1 2 0 0 3 (25.0) | 1.00* |
| Oral mucositis                       | 0 2 2 0 4 (36.4) | 1 1 0 0 2 (16.7) | 0.371* |
| Xerostomia                           | 0 3 0 0 3 (27.3) | 1 1 0 0 2 (16.7) | 0.640* |
| Hepatobiliary disorders              | 0 0 0 0 0 (0.0) | 1 0 0 0 1 (8.3) | 1.000* |
| Skin and subcutaneous tissue disorders| 0 0 0 0 0 (0.0) | 1 0 0 0 1 (8.3) | 1.000* |

CTCAE, Common Terminology Criteria for Adverse Events.
*Fisher’s exact test.

FIGURE 4 | Kaplan-Meier curves for (A) progression-free survival and (B) overall survival of the ICI+RT, RT alone, and ICI alone groups. ICI, immune checkpoint inhibitors; RT, radiotherapy; ICI+RT, pembrolizumab combined with RT.

sites that share the same antigens they are primed against—an abscopal effect.

Considering these effects of RT on immune system function, both locally and systemically, studies have focused on the clinical implication of RT combined with systemic ICI, which reverses the immunosuppressive effect of tumors, thus facilitating anti-tumor immunity together with RT. A few studies have reported the outcomes of combination treatment for cutaneous melanoma. Hiniker et al. reported that 11 of 22 patients treated with ICI+RT experienced better than SD, suggesting that a subset of patients benefit from combination therapy (33). Twyman-Saint Victor et al. reported that 18% of 22 patients treated with ICI+RT experienced better than SD, suggesting that a subset of patients benefit from combination therapy (33). Twyman-Saint Victor et al. reported that 18% of 22 patients treated with ICI+RT experienced better than SD, suggesting that a subset of patients benefit from combination therapy (33).

Frontiers in Oncology | www.frontiersin.org 7 September 2019 | Volume 9 | Article 835

Radiation-induced lymphopenia, which is more frequently observed in long-course than in short-course RT, might also be associated with this outcome. Many studies are currently ongoing to determine the optimal RT dose and site to induce a more abscopal effect.

Until now, only one study has reported the result of combined RT and anti-PD-1 therapy in seven mucosal melanoma patients (36). Regarding response rates, four of seven patients (57.1%) achieved CR or PR. In our study, three among seven lesions of the RT+ICI group and 11 among all 21 lesions achieved better combined with ICI. However, the number of patients included in this analysis was very small; thus, future clinical trials are needed. Unfortunately, we could not assess whether RT had a synergistic effect on systemic outcomes, given that our study cohort included heterogeneous clinical situations at RT. In our study, no abscopal effect was observed, and out-field progression was not improved by combination with ICI. This result could be because most lesions were treated with conventional fractions (67.7%), by which the stimulator of the interferon genes pathway is not activated and thus interferon levels are not increased (35). Radiation-induced lymphopenia, which is more frequently observed in long-course than in short-course RT, might also be associated with this outcome. Many studies are currently ongoing to determine the optimal RT dose and site to induce a more abscopal effect.
than PR. This result is similar to or slightly higher than that of previous reports; however, the strength of our study is that it is the only study comparing the efficacy of combination therapy to that of RT alone.

In our study, 3 (13%) patients experienced grade 3 AEs, and no AE > Grade 4 was observed. Adding pembrolizumab to RT did not increase the rate of AEs in our patients. This result is similar to recent evidence from a prospective trial investigating the safety of multisite stereotactic body radiotherapy (SBRT) followed by pembrolizumab in metastatic solid tumors (37). The trial revealed that 10% of 62 patients experienced treatment-related severe toxicity (≥Grade 2), with a median follow-up of 5.5 months. We can assume that combined ICI+RT might not synergistically increase treatment-related toxicities, given that these results are similar to those of SBRT or pembrolizumab monotherapy. However, more results from a larger number of patients with long-term follow-up are necessary to ensure the safety of combined treatment.

Our study has limitations besides its retrospective design. First, the number of patients included was small. Because of its rarity, a limited number of studies on mucosal melanoma patients have been conducted to date, and large randomized clinical trials are difficult to organize. Second, patients treated with ICI+RT were recently treated compared to those treated with RT alone. However, this approach might include little bias given that the treatment of mucosal melanoma and the RT technique have not changed that much during this period.

In conclusion, we investigated the effect of RT combined with ICI on LC in mucosal melanoma patients, especially comparing combined treatment with RT alone. RT might be helpful in improving the LC of mucosal melanoma, either in the primary or metastatic setting. We believe that ICI might have a radiosensitizing effect and may increase LC without causing severe toxicity. Further clinical trials are warranted to refine the role of RT when combined with ICI in mucosal melanoma patients. We have initiated a phase II study to determine the effects of RT in Asian patients with melanoma who have more mucosal type than their Western counterparts undergoing anti-PD1 (NCT04017897).

DATA AVAILABILITY
The datasets generated for this study are available on request to the corresponding author.

AUTHOR CONTRIBUTIONS
All authors listed have made a substantial, direct and intellectual contribution to the work, and approved it for publication.

FUNDING
This study was supported by a faculty research grant of Yonsei University College of Medicine (6-2018-0163).

REFERENCES

1. Chang AE, Karnaeh LH, Mench HR. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer. (1998) 83:1664–78. doi: 10.1002/(SICI)1097-0142(19981015)83:8<1664::AID-CNCR23>3.0.CO;2-G

2. Rapini RP, Golitz LE, Greer RO Jr, Krekorian EA, Poulson T. Primary malignant melanoma of the oral cavity. A review of 177 cases. Cancer. (1985) 55:1543–51. doi: 10.1002/1097-0142(19850401)55:7<1543::AID-CNCR2825070223>3.0.CO;2-F

3. Kim et al. RT Combined With Anti-PD-1 in Mucosal Melanoma

4. Demaria S, Golden EB, Formenti SC. Role of local radiation therapy in cancer immunotherapy. JAMA Oncol. (2015) 1:1325–32. doi: 10.1001/jamaoncol.2015.2756

5. Dovedi SJ, Adlard AL, Lipowska-Bhalla G, McKenna C, Jones S, Cheadle EJ, et al. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Cancer Res. (2014) 74:5458–68. doi: 10.1158/0008-5472.CAN-14-1258

6. Shariati AB, Lim M, DeWese TL, Drake CG. Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy. Lancet Oncol. (2015) 16:e498–509. doi: 10.1016/S1470-2045(15)00087-8

7. Verschraegen CF, Benjapibal M, Supakarangkoul W, Levy LB, Ross M, Atkinson EN, et al. Vulvar melanoma at the M. D. Anderson Cancer Center: 25 years later. Int J Gynecol Cancer. (2001) 11:359–64. doi: 10.1016/S1073-9290(01)30641-5

8. Harwood AR, Cummings BJ. Radiotherapy for malignant melanoma: a reappraisal. Cancer Treat Rev. (1981) 8:271–82. doi: 10.1016/0735-7907(81)80011-4

9. Lazarev S, Gupta V, Hu K, Harrison LB, Bakst R. Mucosal melanoma of the head and neck: a systematic review of the literature. Int J Radiat Oncol Biol Phys. (2014) 90:1108–18. doi: 10.1016/j.ijrobp.2014.03.042

10. Rapini RP, Golitz LE, Greer RO Jr, Krekorian EA, Poulson T. Primary malignant melanoma of the oral cavity. A review of 177 cases. Cancer. (1985) 55:1543–51. doi: 10.1002/1097-0142(19850401)55:7<1543::AID-CNCR2825070223>3.0.CO;2-F

11. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. (2010) 363:711–23. doi: 10.1056/NEJMoa1003466

12. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. (2015) 372:320–30. doi: 10.1056/NEJMoa1412082

13. Weber JS, D’Angelo SP, Minor D, Hodi FS, Gutierrez R, Neyns B, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. (2010) 363:711–23. doi: 10.1056/NEJMoa1003466

14. Demaria S, Golden EB, Formenti SC. Role of local radiation therapy in cancer immunotherapy. JAMA Oncol. (2015) 1:1325–32. doi: 10.1001/jamaoncol.2015.2756

15. Dovedi SJ, Adlard AL, Lipowska-Bhalla G, McKenna C, Jones S, Cheadle EJ, et al. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Cancer Res. (2014) 74:5458–68. doi: 10.1158/0008-5472.CAN-14-1258
17. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). *Eur J Cancer*. (2009) 45:228–47. doi: 10.1016/j.ejca.2008.10.026

18. Hamid O, Puzanov I, Dummer R, Schachter J, Daud A, Schadendorf D, et al. Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. *Eur J Cancer*. (2017) 86:37–45. doi: 10.1016/j.ejca.2017.07.022

19. Ribas A, Hamid O, Daud A, Hodi FS, Wolchok JD, Keeford R, et al. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. *JAMA*. (2016) 315:1600–9. doi: 10.1001/jama.2016.4059

20. Shousharti AN, Munhoz RR, Kük D, Ott PA, Johnson DB, Tsai KK, et al. The efficacy of anti-PD-1 agents in acral and mucosal melanoma. *Cancer*. (2016) 122:3354–62. doi: 10.1002/cncr.30259

21. Maeda T, Yoshino K, Nagai K, Ooku S, Kato M, Hiura A, et al. Efficacy of nivolumab monotherapy against acral lentiginous melanoma and mucosal melanoma in Asian patients. *Br J Dermatol*. (2018) 180:1230–1. doi: 10.1111/bjd.17434

22. D’Angelo SP, Larkin J, Sosman JA, Lebbe C, Brady B, Neys J, et al. Efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with mucosal melanoma: a pooled analysis. *J Clin Oncol*. (2017) 35:226–35. doi: 10.1200/JCO.2016.67.9258

23. Fertil B, Malaise EP. Intrinsic radiosensitivity of human cell lines is correlated with radiosensitivity of human tumors: analysis of 101 published survival curves. *Int J Radiat Oncol Biol Phys*. (1985) 11:1699–707. doi: 10.1016/0360-3016(85)90223-8

24. Lee Y, Auh SL, Wang Y, Burnette B, Wang Y, Meng Y, et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cell: changing strategies for cancer treatment. *Blood*. (2009) 114:589–95. doi: 10.1182/blood-2009-02-206870

25. Wada H, Nemoto K, Ogawa Y, Hareyama M, Yoshida H, Takamura A, et al. A multi-institutional retrospective analysis of external radiotherapy for mucosal melanoma of the head and neck in Northern Japan. *Int J Radiat Oncol Biol Phys*. (2004) 59:495–500. doi: 10.1016/j.ijrobp.2003.11.013

26. Gilligan D, Slevin NJ. Radical radiotherapy for 28 cases of mucosal melanoma in the nasal cavity and sinuses. *Br J Radiol*. (1991) 64:1147–50. doi: 10.1259/bjd/0007-1285-64-768-1147

27. Sause WT, Cooper JS, Rush S, Ago CT, Cosmatos D, Coughlin CT, et al. Fraction size in external beam radiation therapy in the treatment of melanoma. *Int J Radiat Oncol Biol Phys*. (1991) 20:429–32. doi: 10.1016/0360-3016(91)90053-7

28. Topalian SL, Szol M, McDermott DF, Kluger HM, Carvajal RD, Sharifman WH, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. *J Clin Oncol*. (2014) 32:1020–30. doi: 10.1200/JCO.2013.53.0105

29. Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Keeford R, et al. Anti-programmed-death-death receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. *Lancet*. (2014) 384:1109–17. doi: 10.1016/S0140-6736(14)60958-2

30. Bernstein MB, Krishnan S, Hodge JW, Chang JY. Immunochemistry and stereotactic ablative radiotherapy (ISABR): a curative approach? *Nat Rev Clin Oncol*. (2016) 13:516–24. doi: 10.1038/nrclinonc.2016.30

31. Brooks ED, Chang JY. Time to abandon single-site irradiation for inducing abscopal effects. *Nat Rev Clin Oncol*. (2018) 16:123–35. doi: 10.1038/s41571-018-0119-7

32. Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. *N Engl J Med*. (2012) 366:925–31. doi: 10.1056/NEJMoa1112824

33. Hiniker SM, Reddy SA, Maecker HT, Subrahmanyan PB, Rosenberg-Hasson Y, Swetter SM, et al. A prospective clinical trial combining radiation therapy with systemic immunotherapy in metastatic melanoma. *Int J Radiat Oncol Biol Phys*. (2016) 96:578–88. doi: 10.1016/j.ijrobp.2016.07.005

34. Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauleen KE, Steleki E, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. *Nature*. (2015) 520:373–7. doi: 10.1038/nature14292

35. Deng L, Liang H, Xu M, Yang X, Burnette B, Arina A, et al. STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors. *Immunity*. (2014) 41:843–52. doi: 10.1016/j.immuni.2014.10.019

36. Kato J, Hida T, Someya M, Sato S, Sawada M, Horimoto K, et al. Efficacy of combined radiotherapy and anti-programmed death 1 therapy in acral and mucosal melanoma. *J Dermatol*. (2019) 46:328–33. doi: 10.1111/1346-8138.14805

37. Luke JJ, Lemons JM, Karrison TG, Pitroda SP, Melotek JM, Zha Y, et al. Safety and clinical activity of pembrolizumab and multisite stereotactic body radiotherapy in patients with advanced solid tumors. *J Clin Oncol*. (2018) 36:1611–8. doi: 10.1200/JCO.2017.76.2229

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Kim, Chang, Roh, Oh, Chung, Skin and Koom. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.